CMS has obtained the clinical trial approval notice for the new indication of chronic obstructive pulmonary disease for the Class 1 new drug MG-K10 humanized monoclonal antibody injection
CMS has received approval from the National Medical Products Administration (NMPA) of China to conduct clinical trials for the Class 1 new drug MG-K10 humanized monoclonal antibody injection in chronic obstructive pulmonary disease (COPD). The co-development rights and exclusive commercialization rights for the drug are owned by CMS, and the approval notice was issued on September 29, 2025
According to the Zhitong Finance APP, CMS (00867) announced that the group has co-development rights (excluding atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 new drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (MG-K10), which received the drug clinical trial approval notice from the National Medical Products Administration (NMPA) of China on September 29, 2025. The NMPA has agreed to conduct clinical trials for MG-K10 for chronic obstructive pulmonary disease (COPD)
